|
Bebtelovimab USG Supply Ending
Please be aware of the following important changes regarding the United States Government (USG) supply of Bebtelovimab:
- Bebtelovimab USG supply is expected through the week of August 15th at full threshold and August 22nd at lower threshold.
- Bebtelovimab is expected to be commercially available for purchase starting the week of August 15, 2022. States/territories and providers will be eligible to purchase directly through the distributor; Lilly is not planning state-specific procurement contracts. Information on how commercial access to Bebtelovimab can be found in the next section.
As commercial product becomes available, please consider leveraging USG supply to fill gaps for the under and uninsured within your jurisdictions.
Consequently, we encourage you to plan accordingly and be prepared for potential limitations in Bebtelovimab order fulfillment.
At this time we are not certain when Bebtelovimab ordering capabilities will be turned off in HPoP, but please be aware that supply is low and is not expected to be replenished by the federal government once depleted. Additionally, Bebtelovimab reporting requirements even after the end of USG supply is currently being discussed and more information is expected soon.
Paxlovid Dispensing Rates in Various SVI Localities
In reviewing administration data and comparing against hospitalizations, it revealed that Paxlovid is being dispensed at a lower rate in areas of medium to high social vulnerability index (SVI) across the Commonwealth (Image 1). Some of the reasons for the low dispensing rates in these communities include:
- Patients having the knowledge and resources to test for COVID-19 upon symptom onset
- Patients having the knowledge and resources to access a healthcare provider if positive
- Providers prescribing alternative therapies, including Molnupiravir and Bebtelovimab
Paxlovid is available at clinical sites in these communities and medium and high SVI counties actually have a higher number of courses per population pre-positioned than compared to low SVI counties (Image 2). We strongly encourage providers to assess all COVID-19 positive patients for Paxlovid eligibility and prescribe Paxlovid if appropriate. Providers can locate Paxlovid using the COVID-19 therapeutic locator tool.
If you'd like facility specific information please reach out to covid19therapeutics@vdh.virginia.gov.
Image 1. Paxlovid Courses Dispensed and New COVID Hospitalizations per 100K by EDI Category
 Image 2. Paxlovid Availability in Low, Medium and High SVI localities as of August 3rd, 2022
     Deployment of Additional Paxlovid Courses by Feds
Equitable distribution of COVID-19 therapeutics remains a high priority. In an effort to reach vulnerable communities, the federal government launched a new initiative to pre-position Paxlovid in areas of high social vulnerability. Emails were sent to nearly 9000 providers for a one-time distribution of 20 courses of Paxlovid. The outreach targeted sites in counties with high SVI and low dispensing rates of oral antivirals. The goal was to make the product more readily available to quickly treat patients in vulnerable areas.
Bebtelovimab Commercial Access
Sites with existing AmerisourceBergen Accounts:
- Immediate access to Bebtelovimab will be granted to all existing AmerisourceBergen accounts
Sites without an existing AmerisourceBergen Account:
AmerisourceBergen will sell to licensed and approved customers regardless of current HPoP participation.
Additional Support: For any questions regarding access to Bebtelovimab contact c19therapies@amerisourcebergen.com
Paxlovid Shelf-Life Extension: Drug Information Update
FDA has authorized extended expiration dates for these lots to reflect the 12-month product shelf-life (see Table 1 below), when stored according to the storage conditions detailed in the Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid.
Table 1: Extended Expiry Dating for Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use) Authorized under EUA 105
|
